Skip to content

Polyphenol Rich Supplementation on Markers of Recovery From Intense Resistance Exercise

Polyphenol Rich Supplementation on Markers of Recovery From Intense Resistance Exercise

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03540602
Acronym
PRSRE
Enrollment
20
Registered
2018-05-30
Start date
2018-05-01
Completion date
2018-08-31
Last updated
2018-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Soreness

Keywords

Polyphenol rich supplementation, Tart cherry, Lifting, Recovery

Brief summary

Strength training is commonly used as an intervention to increase muscle mass, thus improving a person's ability to undertake activities of daily living, or enhance athletic performance. The strength training regimen itself, while ultimately having beneficial effects, causes muscle fibers to be damaged, which the body has to recover from. As the body recovers, it rebuilds the muscle tissue and after multiple consecutive bouts of strength training, the muscle eventually becomes larger and stronger. Thus, it is the recovery from strength training exercise that ultimately determines how well the body adapts. Where inadequate recovery could eventually lead to overtraining and/or injury, optimizing the recovery process from strength training could maximize strength training adaptations. This concept of optimizing recovery has led to development of many supplements, including antioxidants, which may reduce the damage associated with strength training activities and therefore enhance positive adaptations. The purpose of this study is to assess the ability of a polyphenol rich supplementation to aid the recovery process from a demanding bout of resistance exercise

Interventions

DIETARY_SUPPLEMENTTart Cherry

NordicCherry Tart Cherry Extract Powder 500 mg from Specnova, inc

Sponsors

Specnova, inc
CollaboratorUNKNOWN
Jacksonville University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

To ensure that all subjects and researchers are unaware of the treatment assignments we will have one outside individual that will possess the knowledge of which subjects are given which supplement and which were given a placebo. This information will remain confidential until the study has been concluded. At the conclusion of the study, participants will be informed of which condition they were assigned. in an event of an emergency or the participant decides not to participate his condition will be revealed.

Intervention model description

20 male participants will start with a familiarization visit where they will receive either the placebo supplement or the polyphenol rich supplement that they will take for 7 days. After taking the supplement, the participants will come back and run through the acute resistance exercise protocol as well as return the next day for a post test. Next, the participants will undergo a wash out phase where they will not take any supplementation. At the end of these 2 weeks, the participants will then take the other supplement (i.e. if they took the polyphenol rich supplement in the first phase they will take the placebo supplement in the second phase). After a week of taking their assigned supplement, participants will complete the acute resistance exercise protocol and the post test.

Eligibility

Sex/Gender
MALE
Age
21 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* 6 months of resistance training experience with barbel back squat exercise

Exclusion criteria

* Not currently taking any antioxidant supplements, not currently using any hormone replacement therapy or anabolic androgenic steroids.

Design outcomes

Primary

MeasureTime frameDescription
Assessment of Oxidative Stress7 weeksBlood analyses will be used, 8 mL of blood will be taken from the participant six times per condition. The blood will be centrifuged to separate the serum/ plasma and analyzed by enzyme- linked immunosorbent assay (ELISA) for c- reactive protein and creatine kinase, and oxidative damage

Secondary

MeasureTime frameDescription
Muscle soreness7 weeksSubjects will mark a line on a 10cm scale that corresponds to the amount of muscular soreness they currently perceive
Vertical Jump Performance7 weeksSubjects will be instructed to stand on a NeuroCom Balance Manager forceplate with hands on hips. Subjects will then be instructed to perform 3 consecutive vertical jumps, as high as possible with minimal time between jumps. The jumps will later be assessed for power production.

Countries

United States

Contacts

Primary ContactHeather Hausenblaus
hhausen@ju.edu904-256-7975
Backup ContactDavid Hooper
dhooper4@ju.edu904-256-7985

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026